journal article·2025-08-06

Hyperbranched Poly(citric acid) Mitigated Iron Overload Damage via Iron Chelation and Antioxidation

Mengdi Liu, Xinyue Liang, Chuhang Hong, Wenying Wei, Meizhen Yin, Yanan Zhao, Xiaopei Wu, Honglian Dai

Nano Letters· Volume 25· Issue 31
Publisher page

Abstract

Iron overload (IO) is a condition of excessive iron deposition in various organs, which can cause pathological changes. In the treatment of IO, iron chelators have toxic side effects, and antioxidants cannot decrease iron deposition. Herein, a biodegradable hyperbranched poly(citric acid) (PCA) was synthesized, and the therapeutic effects of PCA on IO were investigated based on liver and bone tissue iron injury mouse models. The results showed that PCA exerted good iron chelation abilities and inhibited iron overload-induced apoptosis, ROS production, and mitochondrial dysfunction. The bone loss model and liver injury model of mice revealed the potential of PCA in iron overload treatment. PCA reduced iron deposition in bones and improved bone tissue morphology and microstructure. Moreover, PCA inhibited the oxidative stress level, thereby reducing the degree of liver injury. In summary, these findings suggested that PCA could be a promising candidate for treating iron overload disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · Synthesis and Characterization of Heterocyclic Compounds · Iron Metabolism and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, School of Chemistry, Chemical Engineering and Life Science

Wuhan University of Technology

Medical College

Inner Mongolia Minzu University

School of Intelligent Medicine, China Medical University, No.77, Puhe Road, Shenyang 110122, China

National Energy Key Laboratory for New Hydrogen-ammonia Energy Technologies

Foshan Xianhu Laboratory

Funding

Basic and Applied Basic Research Foundation of Guangdong Province · National Natural Science Foundation of China · Key Research and Development Program of Hubei Province

References (49)

Show source-provided references
1. 10.1182/blood-2018-06-81589410.1182/blood-2018-06-815894 ↗
2. 10.1016/j.bbagen.2011.10.01310.1016/j.bbagen.2011.10.013 ↗
3. 10.1038/s41420-019-0234-y10.1038/s41420-019-0234-y ↗
4. 10.1056/NEJMra100496710.1056/NEJMra1004967 ↗
5. Wang X. · Affiliations College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. Shandong Academy of Chinese Medicine, Jinan, China. College of Traditional Chinese Medicine · 2021 · 9 · 685364
6. 10.1016/S0268-960X(12)70006-110.1016/S0268-960X(12)70006-1 ↗
7. Kumar M. A. · Maedica · 2013 · 8 · 328
8. 10.1016/j.taap.2021.11559610.1016/j.taap.2021.115596 ↗
9. 10.1002/j.2040-4603.2013.tb00494.x10.1002/j.2040-4603.2013.tb00494.x ↗
10. 10.1038/s41413-023-00247-y10.1038/s41413-023-00247-y ↗
11. 10.1016/j.biopha.2021.11138010.1016/j.biopha.2021.111380 ↗
12. 10.1007/s11657-020-00819-z10.1007/s11657-020-00819-z ↗
13. 10.1155/2022/491120510.1155/2022/4911205 ↗
14. 10.1016/j.clinthera.2015.10.00110.1016/j.clinthera.2015.10.001 ↗
15. 10.3390/pharmaceutics1204032910.3390/pharmaceutics12040329 ↗
16. 10.1002/ajh.2402410.1002/ajh.24024 ↗
17. 10.1007/s00415-019-09577-610.1007/s00415-019-09577-6 ↗
18. 10.1002/ajh.2447910.1002/ajh.24479 ↗
19. 10.1007/s00467-012-2170-410.1007/s00467-012-2170-4 ↗
20. 10.3390/ijms2509465410.3390/ijms25094654 ↗
21. 10.1186/1755-8794-2-210.1186/1755-8794-2-2 ↗
22. 10.1186/s12934-019-1064-610.1186/s12934-019-1064-6 ↗
23. 10.1016/j.bioactmat.2022.04.02710.1016/j.bioactmat.2022.04.027 ↗
24. 10.1002/jbm.a.3674810.1002/jbm.a.36748 ↗
25. 10.1089/jmf.2013.006510.1089/jmf.2013.0065 ↗
26. 10.1177/147916411142429710.1177/1479164111424297 ↗
27. 10.3390/metabo1303033110.3390/metabo13030331 ↗
28. 10.1016/j.eurpolymj.2021.11027110.1016/j.eurpolymj.2021.110271 ↗
29. 10.3390/nu1111257610.3390/nu11112576 ↗
30. 10.2174/187652540120401002710.2174/1876525401204010027 ↗
31. 10.1021/acschembio.8b0110010.1021/acschembio.8b01100 ↗
32. 10.1002/med.2186410.1002/med.21864 ↗
33. 10.1002/app.3902810.1002/app.39028 ↗
34. Hamacher-Brady, A. CMLS forum reviews: Mitochondrial damage control; Springer, 2021; Vol. 78, pp 3763–3765.10.1007/s00018-021-03804-y ↗
35. 10.1016/j.arr.2022.10171710.1016/j.arr.2022.101717 ↗
36. 10.1002/jcp.2767810.1002/jcp.27678 ↗
37. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
38. 10.1016/j.mam.2020.10089610.1016/j.mam.2020.100896 ↗
39. 10.21037/tgh.2019.11.1510.21037/tgh.2019.11.15 ↗
40. 10.1016/j.watres.2011.03.00810.1016/j.watres.2011.03.008 ↗
41. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
42. 10.1016/j.bbamcr.2019.11853510.1016/j.bbamcr.2019.118535 ↗
43. 10.1039/C4TB01498G10.1039/C4TB01498G ↗
44. 10.1042/CS2015008710.1042/CS20150087 ↗
45. 10.7717/peerj.261110.7717/peerj.2611 ↗
46. 10.1371/journal.pone.011291510.1371/journal.pone.0112915 ↗
47. Averill-Bates D. A. · 2023 · 121 · 109
48. 10.1159/00048508910.1159/000485089 ↗
49. 10.1016/j.phymed.2024.15546510.1016/j.phymed.2024.155465 ↗